OMERS ADMINISTRATION Corp Sells 50,800 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

OMERS ADMINISTRATION Corp trimmed its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 50.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,800 shares of the company's stock after selling 50,800 shares during the period. OMERS ADMINISTRATION Corp's holdings in Roivant Sciences were worth $601,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock worth $28,000 after buying an additional 1,948 shares in the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Roivant Sciences in the fourth quarter worth about $39,000. PNC Financial Services Group Inc. lifted its position in shares of Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after buying an additional 1,507 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Roivant Sciences by 84.1% in the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock worth $89,000 after buying an additional 3,426 shares in the last quarter. Finally, Blue Trust Inc. raised its position in Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after purchasing an additional 6,667 shares during the period. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, major shareholder Vivek Ramaswamy sold 273,959 shares of the company's stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the transaction, the insider now owns 39,799,611 shares of the company's stock, valued at approximately $456,501,538.17. This represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $10.95, for a total value of $1,095,000.00. Following the completion of the transaction, the chief operating officer now directly owns 1,077,197 shares in the company, valued at approximately $11,795,307.15. This trade represents a 8.49% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,223,959 shares of company stock valued at $13,450,035. 7.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on ROIV. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a research report on Monday, April 21st.

Roivant Sciences Price Performance

Shares of ROIV traded down $0.07 during mid-day trading on Friday, reaching $10.87. 2,442,270 shares of the company's stock traded hands, compared to its average volume of 5,579,306. The stock has a market cap of $7.76 billion, a P/E ratio of -72.46 and a beta of 1.23. The stock's 50-day moving average is $10.53 and its two-hundred day moving average is $11.05. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.